Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome
- PMID: 19482344
- DOI: 10.1016/j.ygyno.2009.05.004
Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome
Abstract
Objective: To describe the operative technique and associated clinical outcomes of patients undergoing rectosigmoid colectomy as a component of secondary cytoreductive surgery for recurrent ovarian cancer.
Methods: Consecutive patients undergoing rectosigmoid colectomy for recurrent epithelial ovarian cancer between 1/01 and 12/07 were retrospectively identified and clinical data abstracted from the medical record. The surgical technique, associated morbidity, and clinical outcomes are described.
Results: Fifty-six patients were identified. The median age at secondary surgery was 56 years; 78.6% had advanced-stage disease at initial diagnosis; 69.6% had grade 3 tumors; 73.2% had serous histology. Complete cytoreduction to no gross residual disease was achieved in 85.7% of cases. Concurrent distal ureterectomy/partial cystectomy was required in 8 cases (14.3%). The median number of regional cytoreductive procedures outside the pelvis was 1 (range=0-4). A stapled coloproctostomy was performed in 98.2% of patients; a protective colostomy/ileostomy was constructed in 7 cases (12.5%), and one patient (1.8%) underwent end colostomy. The median EBL was 500 cm(3) and the median operative time was 225 min. Blood transfusion was administered to 48.2% of patients. Post-operative morbidity occurred in 23.2% of patients, with a bowel fistula rate of 5.4% and a mortality rate of 1.8%. The median LOS was 9 days. Post-operative platinum-based chemotherapy was administered in 73.2% of patients. The median overall survival time from secondary surgery was 38.4 months.
Conclusions: Rectosigmoid colectomy can contribute significantly to a maximal cytoreductive surgical effort for recurrent ovarian cancer. Despite technical differences, including a frequent requirement for resection of the distal urinary tract, morbidity is comparable to rectosigmoid colectomy performed for primary cytoreduction and the associated survival outcome appears favorable.
Similar articles
-
Transverse colectomy in ovarian cancer surgical cytoreduction: operative technique and clinical outcome.Gynecol Oncol. 2008 Jun;109(3):364-9. doi: 10.1016/j.ygyno.2008.02.020. Epub 2008 Apr 8. Gynecol Oncol. 2008. PMID: 18396322
-
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.Gynecol Oncol. 2007 Mar;104(3):686-90. doi: 10.1016/j.ygyno.2006.10.020. Epub 2006 Dec 1. Gynecol Oncol. 2007. PMID: 17141302
-
Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.Cancer. 2007 Feb 15;109(4):685-91. doi: 10.1002/cncr.22447. Cancer. 2007. PMID: 17219441
-
Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.Gynecol Oncol. 2009 Jan;112(1):265-74. doi: 10.1016/j.ygyno.2008.08.033. Epub 2008 Oct 19. Gynecol Oncol. 2009. PMID: 18937969 Review.
-
Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.Gynecol Oncol. 2004 Nov;95(2):273-80. doi: 10.1016/j.ygyno.2004.09.018. Gynecol Oncol. 2004. PMID: 15491746 Review.
Cited by
-
Evaluation of a Simple and Safe Tumor Drilling Technique to Potentiate the Effect of Intraperitoneal Chemotherapy in the Treatment of Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancer: A Matched Retrospective Cohort Study.Cancer Control. 2019 Jan-Dec;26(1):1073274819863778. doi: 10.1177/1073274819863778. Cancer Control. 2019. PMID: 31343898 Free PMC article.
-
Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian Population.Oman Med J. 2015 Sep;30(5):344-52. doi: 10.5001/omj.2015.70. Oman Med J. 2015. PMID: 26421115 Free PMC article.
-
Application and evaluation of transitory protective stoma in ovarian cancer surgery.Front Oncol. 2023 Mar 24;13:1118028. doi: 10.3389/fonc.2023.1118028. eCollection 2023. Front Oncol. 2023. PMID: 37035215 Free PMC article. Review.
-
Total pelvic exenteration for pelvic recurrence after advanced epithelial ovarian cancer--A case report and literature review.J Med Life. 2015 Jul-Sep;8(3):263-5. J Med Life. 2015. PMID: 26351524 Free PMC article. Review.
-
Surgical debulking of ovarian cancer: what difference does it make?Rev Obstet Gynecol. 2010 Summer;3(3):111-7. Rev Obstet Gynecol. 2010. PMID: 21364862 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical